Cancer Research · 2006 · 281 citations · 13 references
MedicineOncologyPharmaceuticsCancer PharmacologyMolecular OncologyProstate DiseaseBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyCancer BiomarkersProstate CancerTargeted Cancer TherapyTargeted TherapyAptamer Targeting LigandsAptamer-based TargetingProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen TargetingPsma Targeting LigandsPsma-targeted TherapyRna Aptamer BindingRna Aptamer Interactions
Abstract We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that “escort aptamers” may be useful for the treatment of specific tumors expressing unique antigen targets. (Cancer Res 2006; 66(12): 5989-92)
13
Nanoparticle-Aptamer Bioconjugates
Omid C. Farokhzad, Sangyong Jon, Ali Khademhosseini et al. · Cancer Research · 2004 · 886 citations · Full text
RNA aptamers as reversible antagonists of coagulation factor IXa
Christopher P. Rusconi, Elizabeth Scardino, Juliana M. Layzer et al. · Nature · 2002 · 512 citations